1526 related articles for article (PubMed ID: 22399173)
1. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
[TBL] [Abstract][Full Text] [Related]
3. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
Isham N; Ghannoum MA
J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
5. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of 100 filamentous fungi: comparison of two diffusion methods, Neo-Sensitabs and E-test, for amphotericin B, caspofungin, itraconazole, voriconazole and posaconazole.
Colosi IA; Faure O; Dessaigne B; Bourdon C; Lebeau B; Colosi HA; Pelloux H
Med Mycol; 2012 May; 50(4):378-85. PubMed ID: 21981028
[TBL] [Abstract][Full Text] [Related]
7. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B
Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
[TBL] [Abstract][Full Text] [Related]
9. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
10. [Agents of otomycosis in Manisa region, Turkey, 1995-2011].
Değerli K; Ecemiş T; Günhan K; Başkesen T; Kal E
Mikrobiyol Bul; 2012 Jan; 46(1):79-84. PubMed ID: 22399174
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
Kachuei R; Khodavaisy S; Rezaie S; Sharifynia S
J Mycol Med; 2016 Mar; 26(1):17-21. PubMed ID: 26852191
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
13. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.
Halliday CL; Chen SC; Kidd SE; van Hal S; Chapman B; Heath CH; Lee A; Kennedy KJ; Daveson K; Sorrell TC; Morrissey CO; Marriott DJ; Slavin MA
Int J Antimicrob Agents; 2016 Oct; 48(4):453-8. PubMed ID: 27562696
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activity of silver nanoparticles against ocular pathogenic filamentous fungi.
Xu Y; Gao C; Li X; He Y; Zhou L; Pang G; Sun S
J Ocul Pharmacol Ther; 2013 Mar; 29(2):270-4. PubMed ID: 23410063
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
Ozcan SK; Mutlu B; Dündar D; Willke A
Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
Kondori N; Svensson E; Mattsby-Baltzer I
Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
19. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Marco F; Pfaller MA; Messer SA; Jones RN
Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
